In Pennsylvania, researchers are using genomic profiling to help future treatment of pancreatic cancer, which is the third leading cause of cancer deaths in the United States and has a low survival rate of 8%. One study found a mutation in the anaplastic lymphoma kinase gene and used targeted therapy for the mutated gene. Another study used existing medicines to improve pancreatic cancer outcomes with similar genetic mutations. The key was using the targeted genetic therapy early on as they found patients who had advanced too far with pancreatic cancer did not benefit as much as patients who were in the earlier stages.
Latest article
Fishway hooks Multus to jointly accelerate cultivated fish
In the United Kingdom, Fishway and Multus Biotechnology have partnered to bring cultivated fish to market faster.
The pact will leverage Fishway's expertise in...
Pirelli unveils biobased tires for Range Rovers
In Milan, tire manufacturer Pirelli has launched the first standard production tire for the global market made with over 70% biobased and recycled materials,...
MIT students design 3D printer that converts home food waste into knick-knacks
In Boston, Massachusetts Institute of Technology students Biru Cao and Qiqing Wang have developed an AI-drive desktop 3D printer that converts household food waste...